oxazoles has been researched along with Hepatitis C, Chronic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brigandi, R; Chuang, WL; Gardner, S; Goodman, Z; Husa, P; Jonas, M; Levine, R; Makhlouf, H; McHutchison, J; Patel, K; Rockey, D; Rodriguez-Torres, M; Schultz, M; Shiffman, M; Stancil, B; Theodore, D; Watson, H; Webster, A | 1 |
1 trial(s) available for oxazoles and Hepatitis C, Chronic
| Article | Year |
|---|---|
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Oxazoles; PPAR gamma; Tyrosine | 2010 |